Edesa Biotech (EDSA) Free Cash Flow (2013 - 2025)
Edesa Biotech (EDSA) posted Free Cash Flow of -$2.1 million for Q4 2025, down 23.62% sequentially from -$1.7 million in Q3 2025, and down 38.41% YoY from -$3.4 million in Q4 2024.
Edesa Biotech (EDSA) Free Cash Flow (2013 - 2025) Analysis & Trends
Edesa Biotech has reported Free Cash Flow for 13 years, with the latest figure at -$2.1 million in Q4 2025.
- Quarterly Free Cash Flow fell 38.41% year-over-year to -$2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.9 million (down 57.32% YoY) and the FY2025 annual result came in at -$7.3 million, down 48.98% from the prior year.
- Free Cash Flow declined to -$2.1 million in Q4 2025 per EDSA's latest filing, from -$1.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$353857.0 in Q3 2021 and troughed at -$7.2 million in Q1 2021.
- A 5-year average of -$2.2 million and a median of -$1.7 million in 2025 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 94.18% in 2022, down 1490.52% in 2022.
- Over 5 years, Free Cash Flow stood at -$3.2 million in 2021, then surged by 44.22% to -$1.8 million in 2022, then advanced by 21.47% to -$1.4 million in 2023, then retreated by 7.87% to -$1.5 million in 2024, then slumped by 38.41% to -$2.1 million in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$2.1 million, -$1.7 million, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.10 Mn |
| Dec 31, 2025 | -2.10 Mn |
| Sep 30, 2025 | -1.70 Mn |
| Sep 30, 2025 | -1.70 Mn |
| Jun 30, 2025 | -1.70 Mn |
| Jun 30, 2025 | -1.70 Mn |
| Mar 31, 2025 | -2.38 Mn |
| Mar 31, 2025 | -2.38 Mn |
| Dec 31, 2024 | -1.52 Mn |
| Dec 31, 2024 | -1.52 Mn |
| Sep 30, 2024 | -976,834.00 |
| Sep 30, 2024 | -976,834.00 |
| Jun 30, 2024 | -856,479.00 |
| Jun 30, 2024 | -856,479.00 |
| Mar 31, 2024 | -1.66 Mn |
| Mar 31, 2024 | -1.66 Mn |
| Dec 31, 2023 | -1.41 Mn |
| Dec 31, 2023 | -1.41 Mn |
| Sep 30, 2023 | -1.43 Mn |
| Sep 30, 2023 | -1.43 Mn |